|
Name |
Fusaripeptide A
|
Molecular Formula | C47H77N7O10 | |
IUPAC Name* |
3-[(3R,6R,9R,12R,15R,18R,22S)-3-[(2S)-butan-2-yl]-18-[(1S)-1-hydroxyethyl]-12,15-dimethyl-6-[(4-methylphenyl)methyl]-2,5,8,11,14,17,20-heptaoxo-22-[(2S)-tridecan-2-yl]-1-oxa-4,7,10,13,16,19-hexazacyclodocos-9-yl]propanamide
|
|
SMILES |
CCCCCCCCCCC[C@H](C)[C@@H]1CC(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)O1)[C@@H](C)CC)CC2=CC=C(C=C2)C)CCC(=O)N)C)C)[C@H](C)O
|
|
InChI |
InChI=1S/C47H77N7O10/c1-9-11-12-13-14-15-16-17-18-19-30(5)37-27-39(57)53-41(33(8)55)46(62)50-31(6)42(58)49-32(7)43(59)51-35(24-25-38(48)56)44(60)52-36(26-34-22-20-28(3)21-23-34)45(61)54-40(29(4)10-2)47(63)64-37/h20-23,29-33,35-37,40-41,55H,9-19,24-27H2,1-8H3,(H2,48,56)(H,49,58)(H,50,62)(H,51,59)(H,52,60)(H,53,57)(H,54,61)/t29-,30-,31+,32+,33-,35+,36+,37-,40+,41+/m0/s1
|
|
InChIKey |
LQJQZJOGDGMAIX-AIWCGGGXSA-N
|
|
Synonyms |
Fusaripeptide A
|
|
CAS | NA | |
PubChem CID | 139591362 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 900.2 | ALogp: | 7.0 |
HBD: | 8 | HBA: | 10 |
Rotatable Bonds: | 19 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 264.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 64 | QED Weighted: | 0.073 |
Caco-2 Permeability: | -5.719 | MDCK Permeability: | 0.00004060 |
Pgp-inhibitor: | 0.988 | Pgp-substrate: | 0.999 |
Human Intestinal Absorption (HIA): | 0.382 | 20% Bioavailability (F20%): | 0.999 |
30% Bioavailability (F30%): | 1 |
Blood-Brain-Barrier Penetration (BBB): | 0.009 | Plasma Protein Binding (PPB): | 94.22% |
Volume Distribution (VD): | 0.514 | Fu: | 4.70% |
CYP1A2-inhibitor: | 0 | CYP1A2-substrate: | 0.014 |
CYP2C19-inhibitor: | 0.098 | CYP2C19-substrate: | 0.051 |
CYP2C9-inhibitor: | 0.35 | CYP2C9-substrate: | 0.009 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.043 |
CYP3A4-inhibitor: | 0.744 | CYP3A4-substrate: | 0.071 |
Clearance (CL): | 2.669 | Half-life (T1/2): | 0.191 |
hERG Blockers: | 0.042 | Human Hepatotoxicity (H-HT): | 0.963 |
Drug-inuced Liver Injury (DILI): | 0.039 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.003 | Maximum Recommended Daily Dose: | 0.4 |
Skin Sensitization: | 0.054 | Carcinogencity: | 0.008 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.003 |
Respiratory Toxicity: | 0.006 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005275 | 0.859 | D0D8XY | 0.390 | ||||
ENC005272 | 0.856 | D0M3FJ | 0.388 | ||||
ENC005271 | 0.834 | D02SBQ | 0.387 | ||||
ENC005273 | 0.825 | D08FJL | 0.362 | ||||
ENC005274 | 0.797 | D09OOV | 0.361 | ||||
ENC005276 | 0.766 | D00ZCN | 0.347 | ||||
ENC003684 | 0.588 | D0M1IO | 0.338 | ||||
ENC003716 | 0.555 | D05HPI | 0.338 | ||||
ENC002057 | 0.504 | D0K7NQ | 0.334 | ||||
ENC002514 | 0.502 | D0J7XL | 0.333 |